Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

ONDANSETRON HYDROCHLORIDE

All products: Limited Use (codes 215, 216, 217, 218, 454, 696)

Other products in the same Health Canada class (A04A, A04AA) — coverage varies; not interchangeable

  • Granisetron (Kytril): limited Use 326, 454, Not a benefit
  • Netupitant + palonosetron (Akynzeo): limited Use 561, 562
  • Ondansetron (Zofran): not a benefit
  • Nabilone (Cesamet): general benefit, Not a benefit
  • Aprepitant (Emend Tri-Pack): limited Use 452, 453

Accel-Ondansetron ODT (Tablet) · DIN 02535319 · 4mg ·

Limited Use — Reason for Use code 215, 216, 217, 218, 454, 696 requiredMarketed · checked 2026-09-20
StatusLimited Use — Reason for Use code 215, 216, 217, 218, 454, 696 required
Write on scriptLU code 215, 216, 217, 218, 454, 696 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 215, 216, 217, 218, 454, 696
Reason for Use code 215 For the treatment of emesis in cancer patients receiving highly emetogenic chemotherapy. Coverage limit: LU Authorization Period: 1 year Reason for Use code 216 For patients receiving intravenous chemotherapy or radiation therapy who have not experienced adequate control with other available anti-emetics. Coverage limit: LU Authorization Period: 1 year Reason for Use code 217 For patients receiving intravenous chemotherapy or radiation therapy who experience intolerable side effects with other anti-emetics. Coverage limit: LU Authorization Period: 1 year Reason for Use code 218 For the treatment of emesis in patients receiving radiation therapy which consists of single fraction treatment to the abdominal cavity, hemi-body irradiation and total body irradiation. Coverage limit: The therapeutic value of Ondansetron Hydrochloride more than 24 hours after the last dose of chemotherapy is unproven. Coverage limit: LU Authorization Period: 1 year Reason for Use code 454 For the treatment of emesis in cancer patients receiving moderately emetogenic chemotherapy (MEC) regimens. Coverage limit: LU Authorization Period: 1 year Reason for Use code 696 For the treatment of emesis in patients receiving palliative care who are refractory to, intolerant to, or have a contraindication to at least two other anti-emetics. Note: Pharmacists and prescribers should be informed of and stay current with a drug product's official indications in accordance with Health Canada's approved product monograph. Some aspects of the above criteria may differ from the official indications as described in the product monograph for the ondansetron product. The Executive Officer's funding of drug products is informed by advice from experts that consider evidence regarding the safety, clinical efficacy, and cost-effectiveness of drug products. Coverage limit: LU Authorization Period: 1 year
1 brand, same coverage
Accel-Ondansetron ODT (Tablet) · DIN 02535319 Manufacturer: Accel Pharma Inc.; listing date 2024-02-29 Health Canada: Marketed since 2023-12-19 · brand ACCEL-ONDANSETRON ODT · ATC A04AA01 ONDANSETRON · form Tablet (orally-disintegrating) · route Oral · ingredients ONDANSETRON 4 MG · company Accel pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Accel-Ondansetron ODT (Tablet): Formulary list price $2.5450/unit (unit not stated in source; not the patient's cost)

Ministry pays: $2.5450 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102417 · Verify on the e-Formulary ↗ (DIN 02535319)

Source record
DIN 02535319: Accel-Ondansetron ODT (Tablet) Raw flags: sec12=Y, sec3=Y Item: 562200029; group id 671; item number 1662; lccId 00102; manufacturer id ACC Source form: None; strength: 4mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $2.5450; ministry $2.5450 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02535319 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102417
Interchangeable products
Auro-Ondansetron ODT (Tablet) · DIN 02511282 · $2.5450 Jamp Ondansetron ODF (Film) · DIN 02541351 · $2.5450 Mar-Ondansetron ODT Tablet · DIN 02514966 · $2.5450 Mint-Ondansetron ODT (Tablet) · DIN 02487330 · $2.5450 Ondansetron ODT (Tablet) · DIN 02481723 · $2.5450 Ondansetron ODT (Tablet) · DIN 02519232 · $2.5450 Ondansetron ODT (Tablet) · DIN 02524279 · $2.5450 Ondissolve ODF (Film) · DIN 02389983 · $2.5450 PMS-Ondansetron ODT Tablet · DIN 02519445 · $2.5450 Zofran ODT (Tablet) · DIN 02239372 · not recorded
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (56:22 Antiemetics and Antinauseants) and how they are covered

Matched class: 56:22 Antiemetics and Antinauseants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: DOXYLAMINE SUCCINATE AND PYRIDOXINE HCL, MECLIZINE HCL Some products covered without a code (check the product listing): NABILONE 56:22 Antiemetics and Antinauseants

GRANISETRON HCL

· 4 products · Listed, not a benefit (1), Limited Use, codes 91, 92, 93, 326, 454 (3) · strengths: 1mg · Tab

NETUPITANT & PALONOSETRON HYDROCHLORIDE

· 1 products · Limited Use, codes 561, 562 · strengths: 300mg & 0.5mg · Cap

ONDANSETRON HCL DIHYDRATE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2mg/mL · Inj Sol-2mL Pk, Inj Sol-4mL Pk

NABILONE

· 10 products · Off-Formulary Interchangeable, not an ODB benefit (4), General benefit (6) · strengths: 0.25mg, 0.5mg, 1mg · Cap

APREPITANT

· 1 products · Limited Use, codes 452, 453 · strengths: 125mg & 80mg · Cap

DOXYLAMINE SUCCINATE AND PYRIDOXINE HCL

· 4 products · General benefit · strengths: 10mg & 10mg · SR Tab

MECLIZINE HCL

· 1 products · General benefit · strengths: 25mg · Tab

DIMENHYDRINATE

· 2 products · Limited Use, codes 481 · strengths: 50mg/mL · Inj Sol (with Preservative) Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 56:22
Full class listing Related classes: 56:04 Antacids and Adsorbents, 56:08 Antidiarrhea Agents, 56:12 Cathartics, 56:16 Digestants, 56:40 Miscellaneous G.I. Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS Adults (18-64 years of age) pms-ONDANSETRON (ondansetron tablets) is indicated for: • the prevention of nausea and vomiting associated with mildly and moderately emetogenic chemotherapy, and radiotherapy. • the maintenance of antiemesis following intravenous doses of ondansetron used for the prevention of nausea and vomiting associated with highly emetogenic chemotherapy, including cisplatin. • the prevention of post-operative nausea and vomiting. 1.1 Pediatrics (<18 years of age) Prevention of Nausea and Vomiting Associated with Mildly and Moderately Emetogenic Chemotherapy • Pediatrics (4-12 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of ondansetron in pediatric patients 4-12 years of age has been established. Therefore, Health Canada has authorized an indication for pediatric use. (see 4.2 Recommended Dose and Dosage Adjustment). • Pediatrics (<4 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for the use of pms-ONDANSETRON in children less than 4 years of age. Prevention of Nausea and Vomiting Associat… https://pdf.hres.ca/dpd_pm/00077211.PDF PM date: April 19, 2006 Source product: PMS-ONDANSETRON; DIN 02258188; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.